Cellectis S.A.

Biotechnology • Healthcare • Paris, France • CLLS (NGM)

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This (CLLS) - Seeking Alpha

Seeking Alpha • Dec 18

Cellectis SA updates patent license agreement with University of Minnesota - MSN

MSN • Dec 31

Cellectis Announces Arbitral Decision in Servier Dispute - TipRanks

TipRanks • Dec 15

Full Phase 1 dataset — Cellectis unveils lasme-cel Phase 2 strategy for r/r B-ALL at R&D Day Oct 16 - Stock Titan

Stock Titan • Oct 16

Wells Fargo Keeps Their Hold Rating on Cellectis SA (CLLS) - The Globe and Mail

The Globe and Mail • Nov 14

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Cellectis S.A. had layoffs?

No layoff events have been recorded for Cellectis S.A. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Cellectis S.A. have?

Cellectis S.A. has approximately 216 employees.

What industry is Cellectis S.A. in?

Cellectis S.A. operates in the Biotechnology industry, within the Healthcare sector.

Is Cellectis S.A. a publicly traded company?

Yes, Cellectis S.A. is publicly traded under the ticker symbol CLLS on the NGM. The company has a market capitalization of approximately $0.49 billion.

Where is Cellectis S.A. headquartered?

Cellectis S.A. is headquartered in Paris, France.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.